Literature DB >> 22107818

Higher prevalence of predicted X4-tropic strains in perinatally infected older children with HIV-1 subtype C in India.

Ujjwal Neogi1, Pravat N Sahoo, Karthika Arumugam, Anders Sonnerborg, Ayesha De Costa, Anita Shet.   

Abstract

BACKGROUND: Coreceptor switch from CCR5 to CXCR4 is considered to be less common in HIV-1 subtype C even in advanced stages of infection. In this study, we have examined viral genotypic coreceptor tropism and its clinical, virological, and host genetic determinants among perinatally infected children in India.
METHODS: Genotypic coreceptor tropism analysis was conducted on env V3 sequences using Geno2pheno with a threshold of 10% false-positive rate. A total of 473 sequences were obtained from 72 isolates amplified from children aged 2-17 years. Factors associated with viral tropism in subtype C infections were studied using logistic regression.
RESULTS: Among the samples, 98.6% (71 of 72) were HIV-1 subtype C. Coreceptor tropism analysis determined 81.7% (58 of 71) as R5 tropic, 9.9% (7 of 71) as X4 tropic, and 8.5% (6 of 71) as R5/X4 tropic or dual-tropic HIV-1 strains. Children with X4 or R5/X4 strains were more likely to be older than those with R5-tropic strains (P < 0.05), have lower CD4 counts (P < 0.05), and have viral populations with greater intrapopulation viral divergence (P < 0.01). Older age was a significant independent predictor for X4 or R5/X4 tropism in these children (P < 0.05). None were identified as being heterozygous or homozygous for the CCR5[INCREMENT]32 deletion.
CONCLUSIONS: The high prevalence of X4 and R5/X4 tropic strains among older perinatally infected children with HIV-1 subtype C in India indicate that this phenomenon is not uncommon as previously thought and suggest that coreceptor transition can occur with longer duration of infection and greater disease progression in this population of perinatally infected children living with HIV-1 subtype C.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22107818     DOI: 10.1097/QAI.0b013e3182405c7b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

Review 1.  HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.

Authors:  Nittaya Phanuphak; Ying-Ru Lo; Yiming Shao; Sunil Suhas Solomon; Robert J O'Connell; Sodsai Tovanabutra; David Chang; Jerome H Kim; Jean Louis Excler
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-24       Impact factor: 2.205

2.  Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C.

Authors:  Ujjwal Neogi; Irene Bontell; Anita Shet; Ayesha De Costa; Soham Gupta; Vishal Diwan; Ranbir S Laishram; Ajay Wanchu; Udaykumar Ranga; Akhil C Banerjea; Anders Sönnerborg
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

3.  Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort.

Authors:  Amare Worku Kalu; Nigus Fikrie Telele; Solomon Gebreselasie; Daniel Fekade; Samir Abdurahman; Gaetano Marrone; Anders Sönnerborg
Journal:  BMC Infect Dis       Date:  2017-01-06       Impact factor: 3.090

4.  Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa.

Authors:  Abu Bakar Siddik; Alexandra Haas; Md Shanawazur Rahman; Shambhu Ganeshappa Aralaguppe; Wondwossen Amogne; Joelle Bader; Thomas Klimkait; Ujjwal Neogi
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

5.  Association of X4 tropism with disease progression in antiretroviral-treated children and adolescents living with HIV/AIDS in São Paulo, Brazil.

Authors:  Flávia Jacqueline Almeida; Mayra Simioni Zaparoli; Denise Helena Moreira; Jaqueline de Souza Cavalcanti; Rosangela Rodrigues; Eitan Naaman Berezin; João Leandro de Paula Ferreira; Marco Aurélio Palazzi Sáfadi; Luis Fernando de Macedo Brígido
Journal:  Braz J Infect Dis       Date:  2013-11-22       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.